|Bid||75.64 x 100|
|Ask||75.65 x 700|
|Day's Range||74.75 - 75.88|
|52 Week Range||63.76 - 82.10|
|PE Ratio (TTM)||7.98|
|Dividend & Yield||2.08 (2.82%)|
|1y Target Est||N/A|
AbbVie Inc's said it would be cautious with drug pricing, especially for Humira, the world's biggest selling drug, sending its shares down 2 percent, despite the drugmaker's quarterly profit narrowly beating estimates. Abbvie CEO Richard Gonzalez said on Friday the company would continue to be "careful and conservative" about pricing, even though the drugmaker has already concluded negotiations with insurers for coverage of its Humira drug in 2017 and 2018. "I'd say even in this last cycle, we have been even a little more conservative than we have been in the past because this (drug pricing) has become such a heated topic in the United States," Gonzalez said.
Does the hepatitis C virus (HCV) market still hold potential for companies like Gilead (GILD)?
We don't think the current price accounts for the company's pipeline.